Israel Englander Puma Biotechnology, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 2,880,888 shares of PBYI stock, worth $9.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,880,888

Previous 3,162,533 8.91%

Holding current value

$9.25 Million

Previous $10.3 Million 28.74%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.25 - $4.03 $633,701 - $1.14 Million	-281,645 Reduced 8.91%	2,880,888 $7.35 Million
Q2 2024 Aug 14, 2024	SELL	$2.92 - $5.83 $14,395 - $28,741	-4,930 Reduced 0.16%	3,162,533 $10.3 Million
Q1 2024 May 15, 2024	BUY	$4.29 - $7.4 $13,788 - $23,783	3,214 Added 0.1%	3,167,463 $16.8 Million
Q4 2023 Feb 14, 2024	BUY	$2.23 - $4.49 $798,328 - $1.61 Million	357,995 Added 12.76%	3,164,249 $13.7 Million
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $466,910 - $642,899	-179,581 Reduced 6.01%	2,806,254 $9.91 Million
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $682,717 - $1.49 Million	308,922 Added 11.54%	2,985,835 $9.23 Million
Q4 2022 Feb 14, 2023	SELL	$2.12 - $5.08 $245,148 - $587,430	-115,636 Reduced 4.14%	2,676,913 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $1.31 Million - $2.21 Million	575,905 Added 25.98%	2,792,549 $6.62 Million
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $500,149 - $1.01 Million	304,969 Added 15.95%	2,216,644 $6.32 Million
Q1 2022 May 16, 2022	BUY	$2.13 - $3.24 $434,777 - $661,352	204,121 Added 11.95%	1,911,675 $5.51 Million
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $116,191 - $268,260	40,769 Added 2.45%	1,707,554 $5.19 Million
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $6.7 Million - $9.49 Million	1,010,130 Added 153.83%	1,666,785 $11.7 Million
Q2 2021 Aug 16, 2021	SELL	$8.98 - $11.6 $1.08 Million - $1.4 Million	-120,695 Reduced 15.53%	656,655 $6.03 Million
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $831,537 - $1.21 Million	88,650 Added 12.87%	777,350 $7.56 Million
Q4 2020 Feb 16, 2021	SELL	$7.78 - $12.13 $1.53 Million - $2.39 Million	-196,640 Reduced 22.21%	688,700 $7.07 Million
Q3 2020 Nov 16, 2020	SELL	$9.5 - $11.14 $2.72 Million - $3.2 Million	-286,840 Reduced 24.47%	885,340 $8.93 Million
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $5.44 Million - $10.3 Million	-775,645 Reduced 39.82%	1,172,180 $12.2 Million
Q1 2020 May 14, 2020	BUY	$6.28 - $14.57 $612,419 - $1.42 Million	97,519 Added 5.27%	1,947,825 $16.4 Million
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $7.62 Million - $12.6 Million	1,172,911 Added 173.15%	1,850,306 $16.2 Million
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $1.96 Million - $2.87 Million	223,564 Added 49.26%	677,395 $7.29 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $7.68 Million - $22.3 Million	-624,573 Reduced 57.92%	453,831 $5.77 Million
Q1 2019 May 14, 2019	SELL	$20.77 - $42.37 $5.28 Million - $10.8 Million	-254,292 Reduced 19.08%	1,078,404 $41.8 Million
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $21.5 Million - $50 Million	1,069,706 Added 406.75%	1,332,696 $27.1 Million
Q3 2018 Nov 14, 2018	SELL	$41.2 - $59.85 $11.7 Million - $17 Million	-283,640 Reduced 51.89%	262,990 $12.1 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $16.6 Million - $23.4 Million	343,180 Added 168.68%	546,630 $32.3 Million
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $3.57 Million - $5.93 Million	-59,754 Reduced 22.7%	203,450 $13.8 Million
Q4 2017 Feb 14, 2018	SELL	$93.85 - $132.45 $19.4 Million - $27.4 Million	-206,769 Reduced 44.0%	263,204 $26 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $33.8 Million - $56.3 Million	469,973	469,973 $56.3 Million

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $146M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account